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Abstract 
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of develop‑
ing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis. 
We seek to critically assess the effectiveness, cost‑effectiveness and safety of AIT in the management of allergic 
rhinoconjunctivitis.
Methods: We will undertake a systematic review, which will involve searching international biomedical databases 
for published, in progress and unpublished evidence. Studies will be independently screened against pre‑defined 
eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and 
appropriate, quantitatively synthesised.
Conclusion: The findings from this review will be used to inform the development of recommendations for EAACI’s 
Guidelines on AIT.
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Background
Allergic rhinoconjunctivitis is a very common chronic 
condition that can result in considerable morbidity and 
impairment of quality of life [1–3]. The disease is trig-
gered by exposure to seasonal and/or perennial allergens 
and, depending on the nature of the allergenic trigger(s) 
and patterns of exposure, symptoms may be persistent 
or intermittent [4]. Allergic rhinitis is typically charac-
terized by symptoms of nasal obstruction, a watery nasal 
discharge, sneezing and itching, and there is often (but 
not invariably) involvement of the conjunctiva, which 
manifests with itching, injection and tearing [5]. There 
may in addition be an impact on the ability to concen-
trate, on school and work performance, [6, 7] and inter-
ference with daily activities and sleep; furthermore, 
allergic rhinitis is a risk factor for the development of 
asthma [8].
Symptoms can, in many cases, be controlled with 
avoidance measures and conventional therapy such 
as oral, intranasal and intraocular H1-antihistamines, 
intranasal corticosteroids and anti-leukotrienes, as 
mono-therapy or in combination [4, 9, 10]. Allergen 
immunotherapy (AIT) is an additional treatment option, 
particularly for those with more troublesome disease 
which remains inadequately controlled by avoidance and 
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pharmacotherapy [11–13]. The problem of uncontrolled 
rhinitis, despite treatment, continues to represent a ther-
apeutic challenge in some patients [14].
The European Academy of Allergy and Clinical Immu-
nology (EAACI) is in the process of developing the 
EAACI Guidelines for AIT, and this systematic review is 
one of five inter-linked evidence syntheses that are being 
undertaken in order to provide a state-of-the-art synopsis 
of the current evidence base in relation to evaluating AIT 
for the treatment of allergic rhinoconjunctivitis, food 
allergy, venom allergy and allergic asthma, and allergy 
prevention, which will be used to inform the formulation 
of key clinical recommendations. This review will focus 
on the effectiveness of AIT using key patient relevant 
outcomes: symptom and/or medication scores and dis-
ease specific quality of life [15]. It will also examine the 
cost-effectiveness and safety of AIT in the management 
of allergic rhinoconjunctivitis.
Methods
Search strategy
A highly sensitive search strategy has been developed, 
and validated study design filters will be applied to 
retrieve articles pertaining to the use of AIT for allergic 
rhinoconjunctivitis from electronic bibliographic data-
bases. We have conceptualized the search to incorporate 
the four elements shown in Fig. 1.
To retrieve systematic reviews, we will use the sys-
tematic review filter developed at McMaster University 
Health Information Research Unit (HIRU) (http://www.
hiru.mcmaster.ca/hiru/HIRU_Hedges_MEDLINE_Strat-
egies.aspx#Reviews). To retrieve randomized controlled 
trials (RCTs), we will apply the Cochrane highly sensitive 
search strategy for identifying RCTs in MEDLINE [16]. 
To retrieve case series, we will use the filter developed 
by librarians at Clinical Evidence: http://clinicalevidence.
bmj.com/x/set/static/ebm/learn/665076.html.
We will search the following databases:
  • Cochrane Library including,
 – Cochrane Database of Systematic Reviews (CDSR)
  – Database of Reviews of Effectiveness (DARE)
  – CENTRAL (Trials)
  – Methods Studies
  – Health Technology Assessments (HTA)
 – Economic Evaluations Database (EED)
  • MEDLINE (OVID)
  • Embase (OVID)
  • CINAHL (Ebscohost)
  • ISI Web of Science (Thomson Web of Knowledge)
  • TRIP Database (http://www.tripdatabase.com)
  • Clinicaltrials.gov (NIH web).
  • Clinical trials register (http://www.clinicaltrialsregis-
ter.eu) launched by the European Medicines Agency 
(EMA)
  • Current controlled trials (http://www.controlled-tri-
als.com)
  • Australian and New Zealand Clinical Trials Registry 
(http://www.anzctr.org.au).
The search strategy has been developed on OVID 
MEDLINE and then adapted for the other databases (see 
Appendix 1). In all cases, the databases will be searched 
from inception to October 31, 2015. Additional refer-
ences will be located through searching the references 
cited by the identified studies, and unpublished work, 
while research in progress will be identified through dis-
cussion with experts in the field. We will invite experts 
who are active in the field from a range of disciplines and 
regions to add to the list of included studies by identify-
ing additional published and unpublished papers they 
are aware of and research in progress. There will be no 
language restrictions employed; where possible, relevant 
literature will be translated into English.
Condion
•Allergic 
rhinoconjuncvis
•Allergic rhinis
Intervenons
•AIT adminsitered 
through any route 
i.e. subcutaneous, 
sublingual, oral, 
intranasal, 
epicutaneous, 
intradermal or 
intra-lymphac
•AIT for different 
allergens (e.g. 
pollens, mites, 
animal dander, 
cockroach and 
mould natural) 
including modified 
allergens 
Outcomes
•Effecveness 
• Cost-effecveness
• Safety
Study designs
• Systemac review 
+/- meta-analysis 
• Randomized 
controlled trial to 
assess 
effecveness
•Cost-effecveness 
or cost-ulity 
analysis to assess 
health economics
•Case series (>300 
paents) to assess 
safety
Fig. 1 Conceptualization of systematic review of allergen immunotherapy for allergic rhinoconjunctivitis
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Inclusion criteria
Patient characteristics
We will focus on studies conducted on patients of any age 
with a physician-confirmed diagnosis of allergic rhino-
conjunctivitis or allergic rhinitis, plus evidence of clini-
cally relevant allergic sensitization (e.g., skin prick test or 
specific-IgE).
Interventions of interest and comparator
This review is focused on AIT for different allergens (e.g. 
pollens, house dust mites, animal dander, cockroach and 
moulds), including modified allergens, administered 
through any route [e.g. subcutaneous (SCIT), sublin-
gual (SLIT), oral, intranasal, epicutaneous, intradermal 
or intra-lymphatic] compared with placebo or any active 
comparator.
Study designs
Systematic reviews of RCTs and RCTs will be used to 
investigate effectiveness, health economic analysis will be 
used to assess cost-effectiveness, and systematic reviews, 
RCTs and case series with a minimum of 300 patients will 
be used to assess safety (smaller case series are excluded 
in order to minimise selection biases).
Study outcomes
Primary
•  Effectiveness, both short-term (i.e. during treatment) 
and long-term (i.e. at least a year after discontinua-
tion of AIT) assessed by symptom and/or medication 
scores [16].
Secondary
  • Assessment of disease specific quality of life
  • Threshold of allergen exposure to trigger symptoms 
in an environmental exposure chamber or allergen 
challenge
  • Safety as assessed by local and systemic reactions in 
accordance with the World Allergy Organization’s 
grading system of side-effects [17, 18]
  • Health economic analysis from the perspective of the 
health system/payer.
Exclusion criteria
The following exclusion criteria will be applied:
  • Reviews, discussion papers, non-research letters and 
editorials
  • Animal studies
  • Quantitative studies not employing systematic review 
or RCT techniques
  • Qualitative studies
  • Case series (less than 300 patients).
Study selection
All references will be uploaded into the systematic 
review software Distiller and undergo initial deduplica-
tion. Study titles will be independently checked by two 
reviewers according to the above selection criteria and 
categorized as: included, not included or unsure. For 
those papers in the unsure category, we will retrieve the 
abstract and re-categorize as above. Any discrepancies 
will be resolved through discussion and, if necessary, a 
third reviewer will be consulted. Full text copies of poten-
tially relevant studies will be obtained and their eligibility 
for inclusion independently assessed. Studies that do not 
fulfil all of the inclusion criteria will be excluded.
Quality assessment strategy
Quality assessments will independently be carried out 
on each study by two reviewers using the relevant ver-
sion of the Critical Appraisal Skills Programme (CASP) 
quality assessment tool for systematic reviews and health 
economic evaluations [19, 20]. RCTs will be assessed 
for generation of allocation sequence, concealment of 
allocation, baseline outcome measurements, baseline 
characteristics, incomplete outcome data, blinding of 
outcome assessor, protection against contamination, 
selective outcome reporting and other risks of bias using 
the Cochrane Risk of Bias Tool. Similarly, we will use 
the quality assessment form produced by the National 
Institute for Health and Clinical Excellence (NICE) to 
critically appraise case series [21]. Any discrepancies 
will be resolved by discussion or, if agreement cannot be 
reached, a third reviewer will arbitrate.
Data extraction, analysis and synthesis
Data will be independently extracted onto a customized 
data extraction sheet in Distiller by two reviewers, and any 
discrepancies will be resolved by discussion or, if agree-
ment cannot be reached, by arbitration by a third reviewer.
A descriptive summary with summary data tables will 
be produced to summarize the literature. If clinically and 
statistically appropriate, meta-analysis using either fixed-
effect or random-effects modeling will be undertaken 
[16]. A narrative synthesis of the data will also be under-
taken. It is expected that it will only be appropriate to 
include the SLIT and SCIT studies in a meta-analysis to 
minimize heterogeneity; studies using other approaches 
will be described narratively.
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Sensitivity and subgroup analyses, and assessment 
for publication bias
Sensitivity analyses will be undertaken by comparing the 
summary estimates obtained by excluding studies con-
sidered to be at high risk of bias with those considered to 
be at low or moderate risk of bias.
Subgroup analyses will be undertaken to compare:
  • Children (5–11) versus adolescents (12–17) versus 
adults (≥18 years)
  • SCIT versus SLIT AIT
  • Mild-to-moderate versus severe disease
  • Aqueous solutions versus tablets in SLIT
  • Modified allergen extracts (allergoids) versus unmod-
ified allergen extracts in SCIT
  • The use of single versus multiple allergens from dif-
ferent biological families in an extract
  • AIT for seasonal versus perennial allergens
  • Pre-seasonal (short term treatment) versus continu-
ous treatment in SCIT
  • Pre-/co-seasonal (short term treatment) versus con-
tinuous treatment in SLIT.
Where possible, publication bias will be assessed 
through the creation of funnel plots, and tested by Egg-
er’s regression test and Begg’s rank correlation test [22, 
23].
Registration and reporting
This review will be registered with the International Pro-
spective Register of Systematic Reviews (PROSPERO): 
http://www.crd.york.ac.uk/prospero/. The Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) checklist will be used to guide the reporting of 
the systematic review: http://www.prisma-statement.org/.
Discussion
This review will involve systematically identifying, cri-
tiquing and synthesizing the evidence on the effec-
tiveness, cost-effectiveness and safety of AIT for the 
management of allergic rhinoconjunctivitis. The review 
will take advantage of and build on other recent system-
atic reviews [24–27]. The findings from this review will 
be used to inform the development of recommendations 
for EAACI’s Guidelines on AIT. We anticipate that this 
review will report in 2016.
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Appendix 1: Search strategy
Search strategy 1
(MEDLINE, EMBASE)
 1. exp Rhinitis/
 2. Rhinitis Allergic Perennial/
 3. Rhinitis, allergic, seasonal/
 4. hayfever.mp.
 5. hay fever.mp.
 6. fever, hay.mp.
 7. seasonal allergic rhinitis.mp.
 8. allergic rhinitides.mp.
 9. allergic rhinitis.mp.
 10. rhiniti*.mp.
 11. pollinosis.mp.
 12. pollenosis.mp.
 13. exp Nasal obstruction/
 14. Conjunctivitis/
 15. Conjunctivitis, Allergic/
 16. conjunctivit*.mp.
 17. rhino-conjunctivit*.mp.
 18. or/1-17
 19. exp Desensitization, Immunologic/
 20. exp Immunotherapy/
 21. Desensitization.mp.
 22. Immunotherapy.mp.
 23. Oral Immunotherapy.mp.
 24. Oral desensitization.mp.
 25. Sublingual Immunotherapy.mp.
 26. Subcutaneous Immunotherapy.mp.
 27. Epicutaneous Immunotherapy.mp.
 28. Intradermal Immunotherapy.mp.
 29. (Intra-lymphatic or intra lymphatic immunother-
apy).mp.
 30. Intranasal Immunotherapy.mp.
 31. Specific Immunotherapy.mp.
 32. Or/19-31
 33. exp Intervention Studies/
 34. Intervention Studies.mp.
 35. Experimental stud*.mp.
 36. exp Clinical Trial/
 37. Trial.mp.
 38. Clinical Trial.mp.
 39. exp Controlled Clinical Trial/
 40. Controlled Clinical Trial.mp.
 41. Randomi?ed Controlled Trial.mp.
 42. exp Placebos/
 43. Placebos.mp.
 44. exp Random Allocation/
 45. Random Allocation.mp.
 46. exp Double-Blind Method/
 47. Double-Blind Method.mp.
 48. Double-Blind design.mp.
 49. exp Single-Blind Method/
 50. Single-Blind Method.mp.
 51. Single-Blind design.mp.
 52. Triple-Blind Method.mp.
 53. Random*.mp.
 54. Search:.tw
 55. Review.pt.
 56. Systematic review.tw.
 57. Meta analysis.mp,pt.
 58. Case series.mp.
 59. (Case$ and series).tw.
 60. Cost:.mp.
 61. Cost effective:.mp
 62. Exp Health Care Costs/
 63. (Costs and Costs Analysis).mp.
 64. Economic evaluation*.mp.
 65. ((cost effective* adj1 analys*) or cost minimi?ation 
analys* or cost benefit analys* or cost utility analys* 
or cost consequence analys* or finances).mp.
 66. Or/33-65
 67. 18 and 32 and 66
Search strategy 2
(Cochrane library, TRIP, CINAHL, ISI Web of Sci-
ence, HTA, EED) (Rhinitis* or allergic rhinitis or allergic 
rhinitides or seasonal allergic rhinitis or hayfever or hay 
fever or poll?nosis or pollenosis or conjunctivit* or allergic 
conjunctivitis or rhino conjunctivitis or rhino-conjuncti-
vitis) and (Immunologic, desensiti* or immunotherapy or 
oral immunotherapy or oral desensiti?ation or sublingual 
immunotherapy or subcutaneous immunotherapy or epi-
cutaneous immunotherapy or intradermal immunotherapy 
or intra-lymphatic immunotherapy or intranasal immu-
notherapy) and (Intervention stud* or experimental stud* 
or trial or clinical trial* or controlled clinical trial or ran-
domi* controlled trial or random allocation or single blind 
method or double blind method or triple blind method 
or random* or systematic review or meta-analysis or case 
series or economic evaluation* or cost effective* analys* or 
cost minimi?ation analys* or cost benefit analys* or cost 
utility analys* or cost consequence analys* or finances)
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